RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Clinical trials for RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.

Never miss a new study

Get alerted when new RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear

Sign up with your email to follow new studies for RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New immune cell therapy targets Tough-to-Treat lymphomas

Disease control Completed

This study tested a new two-part immunotherapy for patients whose Hodgkin or Non-Hodgkin lymphoma has returned or not responded to other treatments. It combined a special antibody (AFM13) with donated immune cells (NK cells) to help the patient's own immune system find and kill c…

Matched conditions: RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 20, 2026 14:47 UTC

RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Get alerted when new RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear

New immune cell therapy targets Tough-to-Treat lymphomas